BRAF and cancer: The cell growth inhibitory activities of newly synthesized compounds were evaluated against four human cancer cell lines, including wild-type BRAF cell lines (PC-3 and A549), and BRAFV600E cell lines (A375, HT-29) using standard MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay in vitro, with Sorafenib as the positive control (Table 3).